glp-1 epilepsy Diabetes Medications Linked to Lower Risk Seizure recurrence after GLP‐1 receptor

Summary of the FDA News Release: The FDA just closed the door on compounded GLP-1s and the market implications are enormous

In COVID-19 patients, an increase in inflammatory cytokines, such as interleukin 6 (IL-6), IL-2, IL-7, IL-10, granulocyte colony-stimulating factor (GCSF), interferon -induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1-alpha (MIP1A), and tumor necrosis factor (TNF-), is observed which is called cytokine storm [5]

Treatment with Dulaglutide has been found to reduce binge eating frequency, body weight, body mass index, body fat percentage, and glycated hemoglobin in diabetic patients with binge eating disorder

Through this intracellular coupling, astrocytes supply neurons with cysteine or cysteinyl-glycine derived from exported GSH, thereby supporting neuronal GSH synthesis and resistance to damaging, redox-driven processes (Kwon et al., 2019)